Quotient Biodiagnostics is a transfusion diagnostics group that serves major transfusion diagnostic companies as a product development and supply chain partner and also supplies products directly to the blood banking community. The group is developing a next‑generation automation platform for transfusion diagnostics intended to improve clinical decision‑making and laboratory efficiency. Quotient’s North American sales and marketing business is based in the USA, while Alba Bioscience is its product development and manufacturing arm. The company is pursuing plans to build a new facility to expand its liquid reagent business in Scotland. Management has appointed Ed Farrell (formerly of Siemens Healthcare Diagnostics) as corporate President to lead the automation platform project toward commercial launch. Operationally the company reports key business areas with revenue growth exceeding 50% versus the prior year and has raised significant new equity to fund development and expansion. Quotient Biodiagnostics is a transfusion diagnostics group that supplies trusted transfusion diagnostics products to the US blood banking community. Its products are manufactured by Alba Bioscience, the group's Scotland-based product development and manufacturing arm. Quotient Biodiagnostics, Inc. is the group's North American sales and marketing business. Led by Executive Chairman and Founding Shareholder Paul Cowan, the company is developing an automated transfusion diagnostics platform. The company intends to use new capital to expand US commercial operations and to grow manufacturing and product development operations in Edinburgh, Scotland. It recently completed an $11.2M growth equity financing to support these plans.

Total raised

$16M

Funding rounds

2

Latest round

Equity

Latest activity

Feb 2013